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Abstract Since 1987, keratinocytes have been cul-
tured at the Queen Astrid Military Hospital. These
keratinocytes have been used routinely as auto and
allografts on more than 1,000 patients, primarily to
accelerate the healing of burns and chronic wounds.
Initially the method of Rheinwald and Green was used
to prepare cultured epithelial autografts, starting from
skin samples from burn patients and using animal-
derived feeder layers and media containing animal-
derived products. More recently we systematically
optimised our production system to accommodate
scientiﬁc advances and legal changes. An important
stepwastheremovalofthemouseﬁbroblastfeederlayer
from the cell culture system. Thereafter we introduced
neonatal foreskin keratinocytes (NFK) as source of
cultured epithelial allografts, which signiﬁcantly
increased the consistency and the reliability of our cell
production. NFK master and working cell banks were
established, which were extensively screened and
characterised. An ISO 9001 certiﬁed Quality Manage-
ment System (QMS) governs all aspects of testing,
validation and traceability. Finally, as far as possible,
animal components were systematically removed from
the cell culture environment. Today, quality controlled
allograft production batches are routine and, due to
efﬁcientcryopreservation,stocksarecreatedforoff-the-
shelf use. These optimisations have signiﬁcantly
increased the performance, usability, quality and safety
of our allografts. This paper describes, in detail, our
current cryopreserved allograft production process.
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Introduction
In the late 1970s, Rheinwald and Green described a
method for serial cultivation of human epidermal
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a mitogen-rich medium containing fetal bovine serum
(Rheinwald and Green 1975, 1977). O’Connor et al.
(1981) reported the use of autologous keratinocyte
cultures for the treatment of burns, and over time an
increasing number of culture and delivery systems of
epithelial grafts were developed, mainly in the burn
care ﬁeld (Madden et al. 1986; Herzog et al. 1988;
Burt et al. 1989; Compton et al. 1990; De Luca et al.
1989; Bolivar-Flores et al. 1990; Fratianne et al.
1993; Phillips et al. 1993; Rue et al. 1993; Teepe
et al. 1993a; Brychta et al. 1995, Rivas-Torres et al.
1996; Carsin et al. 2000; Hiroko et al. 2001; Koller
et al. 2002; Chester et al. 2004), but also in
dermatology (Roseeuw et al. 1989; Teepe et al.
1990; De Luca et al. 1992; Marcusson et al. 1992;
Teepe et al. 1993b; Lindgren et al. 1998; Beele et al.
2005), otology (Somers et al. 1997a; Somers et al.
1997b) and stomatology (Tsai et al. 1997). Unfortu-
nately, due to wide patient-to-patient variation and
the lack of controlled clinical research, it is currently
difﬁcult to tell whether there is a place for cultured
epithelial grafts in the treatment of major burns
(Wood et al. 2006). Nevertheless, since 1987,
cultured epithelial grafts were produced by the
Keratinocyte Bank of the Queen Astrid Military
Hospital and used, with some success, to accelerate
the healing of burns and chronic wounds in more than
1,000 patients (Kets et al. 1991; Duinslaeger et al.
1996, 1997a, b). Taking into account the scarcity of
robust scientiﬁc evidence, our personal clinical
experience and concerns relating to cost-effective-
ness, we decided to rationalize the use of keratinocyte
grafts in our hospital. Cultured epithelial allografts
are now mostly used in the burn centre to stimulate
the healing of donor sites and in the chronic wound
care centre to treat hard-to-heal venous leg ulcers. It
was shown that in our centre, keratinocyte allografts
halved the healing time, compared to Op-site treat-
ment, of donor sites (Duinslaeger et al. 1997b), which
allowed more efﬁcient autografting (higher grafting
frequency and/or smaller skin autograft mesh sizes).
Additionally, the donor site surface is most often
signiﬁcantly smaller than the burned surface and thus
requires less keratinocyte allografts.
Toprovidepatients withculturedepithelialgrafts,a
hospital usually needs to approach a specialist tissue
establishment, which is accredited by the National
Competent Authorities. Since the introduction in
March 2004 of the European Union Tissues and Cells
Directive (EUTCD—Directive 2004/23/EC) tissue
banking regulation has become more stringent, not
onlywithrespecttothequalityandsafetyofthesource
material, but also with respect to the processing
environment and the quality and suitability of the
products and reagents used in the production process.
As a result activities such as testing, validation,
traceability, speciﬁcation and veriﬁcation processes
and risk analysis become integral to operations. To
manage and follow up all these different requirements
in a structured and unambiguous way, implementing a
Quality Management System (QMS) has become best
operationalpracticeandisoftenmandatorybynational
law (e.g. Belgian transposition of the EUTCD).
The use of Neonatal Foreskin Keratinocytes
(NFKs) in a deﬁned and animal product-free cell
culture environment has allowed for the development
of an efﬁcient allograft production system with an
excellent safety proﬁle. Epidermal keratinocytes
isolated from neonatal foreskin tissue exhibited
tremendous growth potential, allowing predictable
subculturing schemes, resulting in increased consis-
tency of ﬁnal allograft. The establishment of an
allogeneic cell banking system enabled extensive
safety testing and characterisation of the NFKs in
addition to the mandatory tests (for both autologous
and allogeneic donors) performed on a blood sample
taken from the donor’s biological mother.
All initial cell banking procedures were compliant
with Good Manufacturing Practices (GMP) guide-
lines. The current allograft production is compliant
with the recent (December 2009) Belgian transposi-
tion of the EUTCD and ISO 9001 QMS requirements.
Non-exhaustive examples of measures that have
improved safety and quality in keratinocyte process-
ing include: the use of products that meet United
States Pharmacopeia (USP) or European Pharmaco-
peia (EP) speciﬁcations, or have a CE mark; the
introduction of controlled air environments, and
routine in-process controls and Quality Control
(QC) testing.
Batch productions (typically 60 units) of cryopre-
served allografts, which can be made available off-
the-shelf, avoid the long waiting times (3–4 weeks)
and difﬁculties of timing typically experienced with
cultured epithelial autografts. In addition, we found
cryopreserved allografts to be as effective as cultured
epithelial autografts in in vivo wound healing. In our
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autografts on full thickness burn wounds was disap-
pointing and the lack of a mature dermo-epidermal
junction often resulted in mechanically instable
grafts. Cultured epithelal allografts were shown to
signiﬁcantly accelerate the healing of donor sites and
meshed skin autograft covered burn wounds (Duins-
laeger et al. 1997a, b). Finally, the batch production
of cryopreserved NFK derived allografts offer man-
ufacturing cost-efﬁciencies compared with individ-
ual, small-scale autologous culturing of adult
keratinocytes.
This paper describes in detail our current (i.e.
December 2010) cryopreserved allograft production
processes.
Materials and methods
Safety of raw materials, media and reagents
To guarantee that all used materials were conforming
to applicable EUTCD safety and quality require-
ments, speciﬁcation sheets were prepared and con-
trolled through the QMS. Upon receipt of the
materials, purchase veriﬁcation was performed using
the available speciﬁcation sheets. When applicable,
EDQM (European Directorate for the Quality of
Medicines and Healthcare) certiﬁcates of suitability,
certiﬁcates of analysis, sterility and of origin and
health were requested and ﬁled. For materials and
reagents that come into contact with the cells during
culturing, production and packaging, the highest
quality level was used: USP or EP grade for solid
substances, GMP grade (or its equivalent, e.g. for
‘‘Further Manufacturing Use’’) for reagents and
solutions, and CE marking for packaging materials.
All the media and supplements that were used in the
culturing steps were of deﬁned composition and
known origin, usually plant, microbial or synthetic.
Veriﬁcation of the suitability of the materials was
achieved using stringent quality and safety accep-
tance criteria.
Donor screening
The following exclusion criteria were applied prior to
acceptance and handling of the neonatal foreskin
samples:
• The donor infant’s mother is known to be infected
with Human Immunodeﬁciency Virus (HIV),
Hepatitis B Virus (HBV), Hepatitis C Virus
(HCV), Human T-Lymphotropic Virus (HTLV),
Cytomegalovirus (CMV), syphilis, Epstein-Barr
Virus (EBV), or is suspected of having Creutz-
feldt-Jakob disease;
• The mother has a malignancy, a history of
malignancy, a systemic disease, which requires
chronic medical treatment, or a history of alcohol
or drug abuse;
• The mother received any non-registered drug or
drug under investigation during the 4 weeks
preceding delivery;
• The circumcision site shows clinical signs of
infection;
• The donor infant has a congenital malformation, a
malignancy, or skin disorder.
Peripheral blood samples were obtained, at the
date of birth and according to Good Clinical Practice
(GCP), from the donor’s biological mother. Serum
was separated from the blood, aliquoted, and used for
serological testing (Table 1). A new blood sample
Table 1 Serological tests performed on a peripheral blood
sample from the infant donor’s mother (NFK-5)
Serological tests Initial test Serum conversion test
Anti-HAV Negative ND
HBsAg Negative Negative
Anti-HBs Negative Negative
Anti-HBc Negative Negative
HBV-DNA (PCR) Negative ND
Anti-HCV Negative Negative
HCV-RNA (PCR) Negative ND
Anti-HIV Negative Negative
HIV-Ag Negative ND
HIV-RNA (PCR) Negative ND
Anti-HTLV1&2 Negative ND
TPHA Negative ND
Anti-CMV IgG Negative ND
Anti-CMV IgM Negative ND
Anti-EBV IgG Negative ND
Anti-EBV IgM Negative ND
CMV cytomegalovirus, HAV hepatitis-A virus, HBV hepatitis-
B virus, HCV hepatitis-C virus, HIV human immunodeﬁciency
virus, EBV epstein-barr virus, ND not determined, PCR
polymerase chain reaction
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version) for HIV, HBV and HCV.
Neonatal foreskin samples
Neonatal foreskin samples were obtained after rou-
tine circumcision of newborn males. Informed con-
sent was obtained from the child’s mother. The
foreskin tissue was removed according to GCP and
conventional aseptic techniques. Collected samples
were transferred to 50 ml of basal Epilife
  medium
(Cascade Biologics, now Gibco, Invitrogen Corpora-
tion, USA—a fully deﬁned culture medium with no
serum or non-deﬁned tissue extracts), to which
200 IU/ml penicillin, 200 lg/ml streptomycin and
0.5 lg/ml amphotericin B (antibiotic/antimycotic
1009, Gibco, Invitrogen Corporation) were added,
and transported at 2–8 C to the processing facility.
Primary isolation of epithelial cells
Upon receipt, the exterior of the specimen container
was wiped with 70% isopropanol and placed in a E.C.
class A (class 100 according to U.S. Fed. Standard
209) Biological Safety Cabinet (BSC). The circular
foreskin sample was transferred to a sterile 90 mm
tissue culture dish and cut across its width and
ﬂattened. The amount of tissue was estimated in cm
2.
15 ml Phosphate Buffered Saline (PBS, Lonza) was
added to the dish and the tissue was agitated with
forceps to rinse it. The rinsing process was then
repeated. The skin specimen was then transferred,
epidermal side up, to the sterile lid of a 90 mm dish
(BD Biosciences). Using curved scissors, subcutane-
ous fat and reticular dermis were dissected away,
leaving an intact papillary dermis. The skin was then
washed again in a new dish containing 15 ml PBS
and placed on a clean sterile lid of a 90 mm dish and
the tissue was cut into strips of approximately
0.5 cm 9 1 cm (3–5 strips per foreskin sample,
Fig. 1). The tissue strips were transferred to the
bottom of a 50 ml conical centrifuge tube (BD
Biosciences), which was labelled with the donor code
and contained 10 ml of a 25 U/ml dispase II solution
(Bacillus polymyxa, Roche Diagnostics) with 200 IU/
ml penicillin, 200 lg/ml streptomycin and 0.5 lg/ml
amphotericin B. Ensuring that each piece of tissue
was submerged in the dispase solution, the tube was
securely capped and incubated in a refrigerator for
16–18 h at 2–8 C.
The 50 ml conical tube containing the skin pieces
in dispase solution was retrieved from the refrigerator
and placed in a BSC. Skin pieces and dispase solution
were gently poured into a 90 mm petridish. The
epidermis was separated from the dermis by holding
the dermal side of the skin with forceps and the edge
of the epidermis with a second forceps and then
pulling both skin components apart. All obtained
epidermal pieces were transferred to a sterile 50 ml
tube to which 10 ml of pre-warmed (37 C) Trypsin-
Versene (porcine, Lonza) was added and incubated in
a water bath at 37 C for 30 min, after which the
epidermal pieces were torn into smaller fragments
using forceps. The solution became cloudy as the
individual epidermal cells were released. Immedi-
ately thereafter, 20 ml of 0.025% trypsin inhibitor
(soybean, Sigma–Aldrich) was added and the solution
was pipetted up and down vigorously (approximately
10 times) to further release the epidermal cells. The
cell suspension was passed through a 70 lm cell
strainer (BD Biosciences), which was positioned on
top of a 50 ml conical tube, to remove the remaining
cell clusters and pieces of epidermis. The strainer was
subsequently washed with 2 ml trypsin inhibitor. The
50 ml conical tube with the epidermal cell suspension
was centrifuged for 10 min at 180 g. After centrifu-
gation, the cells were resuspended in 10 ml complete
EpiLife
  medium, i.e. basal EpiLife
  medium sup-
plemented with deﬁned growth supplement S7 (Gib-
co, Invitrogen Corporation), and homogenised by
pipetting up and down. A 20 ll-aliquot of the cell
Fig. 1 A neonatal foreskin (source of NFK-5) cut into 5 strips
each approximately 0.5 cm 9 1c m
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with a 0.5% trypan blue solution (Biochrom) in an
Eppendorf tube. The diluted sample was pipetted in a
Bu ¨rker haemocytometer and the total number of
viable cells was counted. The total amount of primary
isolated cells was then cryopreserved in Synth-a-
Freeze
  cryopreservation medium (Cascade Biolo-
gics, now Gibco, Invitrogen Corporation, USA), a
DMSO-based cryopreservation solution, at a ﬁnal
concentration of approximately 5 9 10
5 cells/ml in
2 ml cryovials (Nunc). These vials comprise the
Primary Cell Bank (PCB).
Epithelial cell culture
The primary isolated epidermal cells were placed in
culture, expanded and banked into a Cell Storage
Banking System (CSBS) comprising a Master Cell
Bank (MCB), a Master Working Cell Bank (MWCB)
and a Working Cell Bank (WCB) (Fig. 2). A cell
bank is a collection of vials of uniform composition
stored under deﬁned conditions and each containing
an aliquot of a single pool of cells. The MCB is the
cell bank that is closest to the initially isolated cells.
The WCB is derived by expansion of one or more
Fig. 2 Diagram of the cell storage bank system (CSBS)
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123vials of the MCB. The cell culturing history and
establishment of the CSBS is described in detail
below. The growth potential of the NFKs was
evaluated under different conditions to determine
deﬁned subculturing schemes. All banking proce-
dures were validated and performed according to
standard operating procedures and GMP guidelines.
Initiation of primary cultures in a deﬁned animal
product-free medium
Primary isolated epidermal cells were seeded in tissue
culture ﬂasks (T-ﬂasks, Falcon, BD Biosciences) at a
density of 10,000–20,000 cells per cm
2. The tissue
culture ﬂasks were additionally coated with a collagen
type-1 solution (PureCol
TM, Advanced Biomatrix,
diluted to 1 lg/ml in PBS), for at least 2 h—but no
longerthan24 h,at37 C.Thecellculturemediumwas
complete EpiLife
  medium, as described previously.
After a maximum of 20 days of primary culture and
visual assessment using phase contrast microscopy,
culturesconsistingofcloningcellsthatreachedatleast
30% conﬂuence 20 days after seeding, were passaged
to a secondary culture. Cultures exhibiting less than
30% conﬂuence were discarded. Figure 3 shows
typical microscopic views of NFKs at different stages
of this initiation phase.
Serial propagation in deﬁned animal product-free
medium
When cultured cells reached an acceptable conﬂu-
ence (80–95%), they were passaged from the primary
culture to the subsequent culture (serial propagation)
until the cells reached the end of their culture
lifespan, or until it became obvious that there was
no need to continue serial subculturing. Cell density
and cumulative population doublings were calculated
at the end of each propagation. Cultures that were
ready for subculturing were washed once with PBS
and then trypsinised with Trypsine-Versene (porcine,
Lonza) for 5–10 min at 37 C. The detachment of the
cells was observed under a phase contrast microscope
and trypsin was inactivated with an equal amount of
deﬁned trypsin inhibitor (soybean, Sigma–Aldrich).
Cells were homogenised by pipetting up and down,
collected in a 50 ml tube and centrifuged for 10 min
at 220 g. The pelleted cells were resuspended in
Fig. 3 Typical microscopic view (magniﬁcation 409) of neonatal foreskin keratinocytes at different stages of the initiation phase.
a Initiation of NFK cells, day 8 after seeding. b Growing colonies at day 11. c Colonies at day 15. d Conﬂuent area at day 20
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  medium (10 ml per trypsinised
tissue culture ﬂask). Homogenisation was again
performed by pipetting up and down with the pipette
tip at the bottom of the tube. A 100 ll-aliquot of the
cell suspension was taken from the tube and diluted
1:1 with a 0.5% trypan blue solution in an Eppendorf
tube. The diluted sample was pipetted in a Bu ¨rker
haemocytometer and the total number of viable cells
was counted. The cells were then reseeded in
collagen coated tissue culture ﬂasks with complete
EpiLife
  medium, at a density of 5,000 cells per cm
2.
The ﬂasks were incubated at 37 Ci n5 %C O 2 and a
relative humidity greater than 95%.
The conﬂuency of the cell cultures was checked on
a regular basis under the microscope and the medium
was refreshed every 2–3 days to conﬂuency. At
conﬂuence, the cells were subcultured and at the end
of passage 2, 4 and 6 the cells were cryopreserved to
establish the MCB, MWCB and WCB, respectively.
Establishment of an MCB
To establish the MCB, approximately 5 9 10
5 viable
primary keratinocytes (one vial) were ampliﬁed by
three culture passages, which represent approxi-
mately 9 population doublings (one passage is
deﬁned as one cell seeding, the primary culture is
considered passage ‘0’). Conﬂuent passage 2 cells
were trypsinised, pooled and counted as described
above (‘Serial propagation in deﬁned animal product-
free medium’). The pooled suspension was centri-
fuged a second time and the pellet was homogenised
in Synth-a-Freeze
  cryopreservation solution and
transferred to cryovials (2 9 10
6 cells in 1 ml per
vial). The vials were frozen (-1 C/min to -50 C
followed by -50 C/min to -150 C) using a con-
trolled rate freezer (Planer, Kryo10, series II) and
stored in the vapour phase of liquid nitrogen (\-
135 C) in a dedicated vessel equipped with automatic
level and temperature control. Since absolute sterility
could not be guaranteed for the initial foreskin
samples, all culturing steps related to the manufac-
turing of the MCB were performed in culturing
medium supplemented with antibiotics (100 U/ml
penicillin, 100 lg/ml streptomycin, 0.25 lg/ml
amphotericin B). Before freezing, the antibiotics
were removed by centrifugation and resuspension of
the cell pellet in antibiotic-free Synth-a-Freeze
 
cryopreservation medium.
Establishment of an MWCB
For the establishment of an MWCB, ﬁve MCB vials
were thawed and propagated for two passages, which
corresponds to approximately seven additional pop-
ulation doublings. The seeding density in each
passage was 5,000 cells/cm
2. Conﬂuent passage four
cultures were trypsinised, pooled and counted as
described above (‘Serial propagation in deﬁned
animal product-free medium’). The pooled suspen-
sion was centrifuged a second time and the pellet was
homogenised in Synth-a-Freeze
  cryopreservation
solution and transferred to cryovials (5 9 10
6 cells
in 1 ml per vial). The vials were frozen and stored as
described above (‘Establishment of an MCB’). No
antibiotics were used in establishing the MWCB.
Establishment of a WCB
The WCB contains the source material for the
allograft production and was derived from the
MWCB. For the establishment of this WCB, 1
MWCB vial was thawed and propagated through
two passages (approximately 7 additional population
doublings). The resulting cells were transferred to
cryo-vials, frozen and stored as described above
(‘Establishment of an MCB’). No antibiotics were
used in the preparation of the WCB.
Production of Allografts
The production of allografts is performed under
aseptic conditions in a class A BSC. The allograft
production protocol is described in detail below. One
WCB vial is thawed and seeded at approximately
5,000 cells/cm
2 in collagen-coated (PureCol
TM,
Advanced Biomatrix) 175 cm
2 tissue culture ﬂasks
(BD Biosciences). Cells are propagated until conﬂu-
ence in complete EpiLife
  medium in 5% CO2
atmosphere and 95% humidity incubator at 37 C. The
propagation takes 4 days and results in approximately
3.5 population doublings. Cells are then detached
from the culturing ﬂasks with Trypsine-Versene
(porcine, Lonza) and subcultured into new collagen-
coated 175 cm
2 tissue culture ﬂasks. Cells are
cultured until just reaching conﬂuency in complete
EpiLife
  medium at 37 C. This typically takes an
additional 4 days and results in approximately 3.5
population doublings. At conﬂuence, the culture
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prepared for harvesting, packaging and freezing.
The ﬁnal form of the keratinocyte allografts can be
viable subconﬂuent sheets (Fig. 4a) or viable cell
suspensions for spray applications (Fig. 4b).
The cells can be removed from the culture ﬂasks,
using Trypsin-Versene (as described before) and
seeded at a density of 13 9 10
6 cells/cm
2 on silicone
membrane coated with plasma polymerised acylic
acid and collagen (PureCol
TM, Advanced Biomatrix)
in a 10 9 10 cm petri dish (Sarstedt), cultured for
24 h at 37 C, and transferred to a custom blister pack
(Charpak Ltd) to which deﬁned cryopreservation
medium is added (Synth-a-Freeze
 , 15 ml). This
blister pack is then packaged in a custom laminated
aluminium foil pack (Oliver Medical) and cryopre-
served using a controlled rate (\1 C/min to -80 C)
freezing process. After freezing, the allograft packs
are transferred to -80 C freezers for medium term
(6 months) storage. The silicone membrane cell
delivery technology has been developed by the
University of Shefﬁeld and Altrika Ltd in the UK.
Full preparation details are outside the scope of the
current review, and are described in details elsewhere
(Haddow et al. 2006).
Cell suspensions that will be used for spray
applications are transferred to cryovials, frozen and
stored as described above (‘Establishment of a
WCB’). For application on the wound bed, cell
suspensions were thawed and washed in PBS and
were co-sprayed with ﬁbrin sealant (Tissucol
  Kit,
Baxter AG) at approximately 50,000 cells/cm
2, using
the Tissomat
  device (Baxter AG). Cell proliferation
rate was not signiﬁcantly reduced when spraying at
maximum 20 psi.
Results
Selection of potent and safe donor cells
Epidermal cells derived from the neonatal foreskins
of donors that met the safety criteria were ﬁrst tested
for growth potential, to select donor cells with a
culture lifespan that is acceptable for long term
reproducible processing. The main evaluation crite-
rion was the cumulative population doubling; only
the cells with a population doubling of at least 25
were further evaluated. Keratinocytes were isolated
from 10 different human neonatal foreskins and
subcultivated to assess their total culturing potential.
Table 2 shows the results of the growth potential
analysis of these 10 human neonatal foreskins
biopsies. Initiation of cell growth was not successful
for the NFK-7 isolate and isolate NFK-10 was not
tested beyond the 4th subculture level because of the
relatively long culture time to reach conﬂuence and
the low multiplication factor in each subculture,
which were an indication of inferior quality and
growth potential. The remaining 8 isolates all reached
at least 9 subculture levels, which in theory would
give rise to more than 1 km
2 of cultured monolayer.
Cells exhibiting a satisfactory growth potential
were cultured under controlled environmental condi-
tions, which were in line with GMP requirements, to
Fig. 4 a A plasma coated silicone membrane supports subconﬂuent keratinocyte growth. Perforations in the substrate allow drainage
of wound exudates. b A mix of a viable keratinocyte suspension and ﬁbrin glue are sprayed onto an uneven burn wound bed
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and WCB). The banked cells themselves were then
tested according to international standards (The
International Conference on Harmonisation of Tech-
nical Requirements for Registration of Pharmaceuti-
cals for Human Use; ICH Topic Q5A ‘‘Quality of
Biotechnological Products: Viral Safety Evaluation
of Biotechnology Products Derived from Cell Lines
of Human or Animal Origin’’). The tests that were
performed and their corresponding results are shown
in Tables 3 and 4. Isolate NFK-1 exhibited the
highest cumulative population doubling, but was
ﬁnally excluded due to positive CMV serology.
Isolate NFK-5 was selected for long-term production
of keratinocyte allografts.
Establishment of a (quality) controlled culturing
scheme
Growth rates and maximal life span of the selected
NFK-5 cells were analysed in detail (Table 5) and, as
expected, the life span was limited. This conclusion
was based on a decreasing proliferation rate. As
shown in Table 5, the growth rate remains very
consistent until passage 8: seeding 5,000 cells/cm
2
systematically resulted into a tenfold increase in cells
after 4 days (equivalent to approximately 3.5
population doublings). From passage 9 onwards, the
culturing time between subsequent passages
increased and the multiplication factor decreased
signiﬁcantly. In addition, the relative proportion of
large, non-proliferative cells also increased signiﬁ-
cantly after passage 8. Light microscopy revealed an
increase in senescent and enlarged cells. Furthermore,
higher passage ([8) conﬂuent cell cultures harboured
less cells than lower passage cultures, and exhibited a
higher ratio of viable cells \30 lm and non-viable
cells[30 lm (Table 6).
Based on the growth potential evaluation analysis
of culturing time and visual cell morphology, passage
8 was selected as the end point for the allografts.
A MCB, MWCB and WCB of NFK-5 cells in
respectively, passages 2, 4 and 6 were set up. Once
the cell banks were established, the initial growth
tests were repeated using the banked NFK-5 cells.
The initial growth curve was reproduced with the
banked cells (Fig. 5).
All manipulations, from donor skin harvesting to
ﬁnal allograft delivery, were described in our quality
system procedures and performed by trained opera-
tors. These procedures included detailed instructions,
actions, and guidance relating to deviations from
expected in-process control parameters. These
parameters were deﬁned by passage number, seeding
density, time to conﬂuence, cell viability and cell
Table 2 Results of the growth potential analysis of epithelial cells isolated from 10 human neonatal foreskins biopsies
Biopsy Culturing Potential
Cell code Surface
(cm
2)
Total cell
yield/cm
2
Seeding
potential
(cm
2)
# Subculture
levels
reached
# Population
doublings
achieved
Cumulative
multiplication
factor
Theoretical
achievable
surface
(km
2)/cm
2
biopsy
Theoretical
achievable
surface (km
2)/cm
2
biopsy at culture
level 9
NFK-1 3 2.13E?05 37.5 15 50 1.12E?15 1.41E?06 112
NFK-2 1.5 1.17E?06 105.3 9 29.6 8.07E?08 5.66E?00 5.7
NFK-3 3 2.23E?06 202.6 13 34.9 3.23E?10 2.18E?02 1.0
NFK-4 1.9 3.79E?06 450.0 10 34.6 2.65E?10 6.28E?02 103
NFK-5 1.8 7.28E?05 102.4 14 45.6 3.86E?14 2.20E?06 10
NFK-6 3 1.63E?06 255.3 9 27.9 2.42E?08 2.06E?00 2
NFK-7 2 4.73E?05 25 NC N/A N/A N/A N/A
NFK-8 2 5.30E?05 41.8 10 29.9 9.83E?08 2.05E?00 1.5
NFK-9 3 1.57E?06 68.9 12 35.98 6.79E?10 1.56E?02 1.6
NFK-10 2 2.70E?06 150 4 12.18 4.64E?03 ND ND
N/A not applicable, NC no cloning of cells, ND not determined
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123morphology. Deviations were evaluated historically,
investigated and the possible impact on the safety or
quality of the end product assessed.
Consistent allograft productions
Many allograft productions, containing cells at pas-
sage 8, have been initiated from the NFK-5 WCB.
Analysis of the growth characteristics of the NFK-5
cells resulted in the cell behaviour under speciﬁc
conditions being well known. This meant that repro-
ducible production schemes could be established,
with a deﬁnable end point and speciﬁc quality criteria
for the ﬁnal allografts. The culturing conditions were
consistent for eight consecutive production runs,
resulting in reproducible end products. Figure 6
shows the consistency of these eight consecutive
production runs with banked NFK-5 cells and their
relation to the initial test curve.
Animal product-free environment
The goal for optimally safe and consistent cell culture
is to use fully deﬁned and animal product-free
products. Over the years, we systematically replaced
animal products with non-animal alternatives. In this
context it is important to note that in the course of
2009 porcine trypsin (Trypsine-Versene, Lonza),
which was frequently used throughout the production
process, was replaced with recombinant ‘trypsin like
dislodging enzyme’ (TrypLE Select, Gibco, Invitro-
gen Corporation). Today, some of our epithelial
allograft delivery formulations using NFKs still
require the use of animal-derived collagen as a
culture substrate.
Discussion
In 1987, the Keratinocyte Bank of the Queen Astrid
Military Hospital started producing cultured epithe-
lial autografts using the method of Rheinwald and
Green. This method uses keratinocytes derived from
adult skin, feeder layers of mitomycin C growth
arrested mouse ﬁbroblasts and serum-containing
media. Since then the culturing system has been
updated to accommodate scientiﬁc and regulatory
advances. Figure 7 shows a detailed history of the
changes introduced to our epithelial graft production
system.
The ﬁrst major change was implemented in 1989,
when we gradually switched from autologous (Phase
Table 3 A cell storage bank system (CSBS) allows for
intensive safety testing on the selected cells (NFK-5)
Microbiological test MCB MWCB WCB
Sterility (EP method) Negative Negative Negative
Mycoplasma Negative Negative Negative
Mycobacterium Negative N/A N/A
In vitro assay for viral
contaminants (MRC-5-,
Vero- and Hela cell lines)
Negative N/A N/A
In vivo assay for viral
contaminants
Negative N/A N/A
Human viruses (PCR)
CMV Negative N/A N/A
HAV Negative N/A N/A
HBV Negative N/A N/A
HCV Negative N/A N/A
Papilloma Negative N/A N/A
Polyoma Negative N/A N/A
HIV-1&2 Negative N/A N/A
EBV Negative N/A N/A
In vitro assay for porcine
viruses
Negative N/A N/A
Extended assay for bovine
viruses
Negative N/A N/A
Bovine viruses (PCR)
Polyoma Negative N/A N/A
Papilloma Negative N/A N/A
All batches and delivery formats resulting from these cells
have the same level of safety assurance
EP European pharmacopeia, PCR polymerase chain reaction,
CMV cytomegalovirus, HAV hepatitis-A virus, HBV hepatitis-
B virus, HCV hepatitis-C virus, HIV human immunodeﬁciency
virus, EBV epstein-barr virus, N/A not applicable
Table 4 Extensive screening of the selected NFK-5 cells
Extensive screening MCB MWCB WCB PPC
Iso-enzyme Human Human N/A N/A
TEM Negative N/A N/A N/A
PERT Negative N/A N/A N/A
Karyology N/A Normal N/A Normal
Tumorogenicity N/A Negative N/A Negative
TEM transmission electron microscopy, PERT product
enhanced reverse transcriptase, PPC post production cells
(passage 15), N/A not applicable
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1231) to allogeneic source material (Phase 2), which
resulted in efﬁcient production planning and conse-
quently an improved availability of epithelial grafts
for surgery.
A second advance enabled the production of
cryopreserved allografts (Phase 3), which allowed
off-the-shelf use and pre-transplantation microbial
testing.
Table 5 Results of NFK-5 growth tests. Primary NFK-5 cells were seeded at a density of 12,800 cells/cm
2 and propagated for 9 days
Passage # Days Cumulative
days
Seeding
density
(cells/cm
2)
Reached
density
(cells/cm
2)
Multiplication
factor
Cumulative
multiplication
factor
Population
doublings
Conﬂuence
at subculture
(%)
0 9 9 12,800 44,720 3.49 3.49 1.80 75
1 4 13 5,000 72,770 14.55 50.85 5.67 98
2 4 17 5,000 35,390 7.08 359.90 8.49 70
3 4 21 5,000 69,753 13.95 5,020.85 12.29 90
4 4 25 5,000 64,012 12.80 64,278.99 15.97 100
5 4 29 5,000 51,235 10.25 658,666.79 19.33 100
6 4 33 5,000 77,963 15.59 10,270,327.84 23.29 100
7 4 37 5,000 51,296 10.26 105,365,347.40 26.65 95
8 5 42 5,000 57,201 11.44 1,205,400,647.38 30.17 98
9 4 46 5,000 38,136 7.63 9,193,831,817.69 33.10 90
10 4 50 5,000 26,846 5.37 49,363,521,795.52 35.52 80
11 5 55 5,000 35,802 7.16 353,462,561,464.65 38.36 85
12 6 61 5,000 29,913 5.98 2,114,625,120,218.42 40.94 90
13 6 67 5,000 22,062 4.41 9,330,571,880,451.73 43.09 95
14 7 74 5,000 28,728 5.75 53,609,733,796,323.50 45.61 98
For each passage, multiplication factors and the total theoretical culture surface area per cm
2 of biopsy were calculated. Population
doublings were calculated as log 2
n, with n = cumulative multiplication factor
Table 6 Evaluation of the
ratio of large non-proliferative
cells ([30 lm) versus small
proliferative cells (\30 lm)
throughout the cell culture life
span of NFK-5 cells
ND not determined
Passage # Total
cells/ml
Viable
cells/ml
Viability
(%)
Cells
[30 lm
Ratio of viable
cells[30 lm/\30 lm
(%)
0 ND 2.19E?05 ND 3.63E?03 1.66
1 3.05E?05 2.93E?05 96.06 6.38E?03 2.18
2 1.81E?06 1.64E?06 90.44 3.41E?04 2.08
3 1.53E?06 1.41E?06 92.28 2.29E?04 1.62
4 5.29E?05 4.99E?05 94.4 1.06E?04 2.12
5 ND 9.04E?05 ND 1.28E?04 1.42
6 ND 1.01E?06 ND 2.75E?04 2.72
7 ND 9.02E?05 ND 2.19E?04 2.43
8 7.47E?05 6.71E?05 89.9 2.05E?04 3.06
9 4.09E?05 3.82E?05 93.4 1.65E?04 4.32
10 1.12E?06 1.01E?06 90.5 6.14E?04 6.08
11 7.36E?05 6.26E?05 85.1 4.68E?04 7.48
12 7.71E?05 7.13E?05 92.6 8.40E?04 11.78
13 6.00E?05 5.37E?05 89.6 7.16E?04 13.33
14 5.91E?05 5.10E?05 86.3 1.05E?05 20.59
15 5.69E?05 4.91E?05 86.3 1.13E?05 23.00
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123The next major change was the removal of the
mouse ﬁbroblast feeder layer from the culturing
system and, shortly thereafter the introduction of
NFKs as source material (Phase 4). Mouse ﬁbroblast
feeder layers support the growth of human keratino-
cytes, but there is a risk that they could introduce
remnants of animal components (e.g. mouse DNA)
into the epithelial allografts. The grafts would then be
deﬁned as xenografts from a regulatory viewpoint.
The introduction of NFKs, in turn, increased the
consistency and the performance of our culturing
system. In contrast to the irregular, unpredictable
growth rates and variable end points associated with
the culture of adult human epidermal keratinocytes
(HEKas), NFKs showed regular and consistent
growth for up to 50 population doublings, even after
more than 5 years of cryopreservation, which is
comparable to established cell lines. This tremendous
proliferation potential allowed the use of more
deﬁned subculturing schemes. HEKas were also
initiated and propagated in our culturing system,
but they never reached the same culture level as the
NFKs. Coolen et al. (2007) reported similar results
for HEKas in a feeder layer free culturing system. In
addition, the establishment of an NFK cell bank
system increased safety, because it enabled extensive
safety testing of the cells themselves in addition to
the usual tests that are traditionally performed on the
blood of the donor. In addition, as the cell source
remains unchanged for several years and numerous
allograft batches, their safety proﬁle for patients
increases because the clinical use of these allografts
is documented for hundreds of applications. The use
of the same cell source for many years also facilitates
the traceability of the allografts. Finally, the use of
banked cell stocks for multiple allograft productions
reduced the risk of mutations associated with serial
cultivation.
Braye et al. (2000) developed a cell bank system
for adult allogeneic keratinocytes, but this approach
has only limited possibilities, mainly due to the
constant need for new donor cells, which results in
repeated safety testing and variations in growth
potential of the starting cells. Our NFK cell banks
were tested for several viral agents, mycoplasmas,
tumorigenicity and karyology. The ﬁnancial chal-
lenges associated with performing these tests for
keratinocytes derived from multiple adult donors is
considerable.
In our system, the use of HEKas would lead to
substantially higher allograft production costs, due to
higher operational and safety testing costs. Moreover,
it may not be possible to reach NFK safety and
quality levels with banked HEKas, which usually
originate from donors that are relatively hard to
screen for safety (e.g. deceased donors and surgical
waste donors). Finally, HEKa allograft consistency
would also be compromised because donor age and
anatomical site of skin harvesting can inﬂuence the
quality and the life span of the cultured cells (data not
shown). NFK allograft consistency is likely to have a
positive inﬂuence on the graft success rate.
Fig. 5 Comparison between the growth curves of NFK-5 cells
in continuous culture and in a banking system
Fig. 6 Overview of 8 different NFK-5 production runs and
comparison with the initial growth test curve
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123Phase 5 saw the introduction of a totally deﬁned
culturing medium and an ISO 9001 certiﬁed QMS,
which led to a further improvement of allograft
quality, safety and consistency. The use of controlled
environment and products that meet USP and/or EP
speciﬁcations or have a CE mark, in process controls
and QC testing are a few examples of the measures
that improved the safety and quality of our allografts.
In addition, all media and reagents that came in
contact with the cells and the end product were
produced in compliance with GMP by specialist
manufacturers.
In Phase 6, which at the time of writing is ongoing,
we aim to progress to a fully deﬁned and animal
product-free cell culture environment, which avoids
the possible transmittance of known and unknown
animal infectious agents (e.g. scrapie and bovine
spongiform encephalopathy) to workers exposed to
thecellculturemediaandreagentsandpatients treated
with allografts (Sun et al. 2004). At present the NFK
delivery formulations, which are clinically available
and minimise the use of animal derived components,
arecellsuspensionsandsubconﬂuentcells seededona
silicone membrane. The latter presentation still
requires the use of animal-derived collagen but
evaluation of a human recombinant Type I collagen
(Coating Matrix Kit, Gibco, Invitrogen Corporation)
forms the focus of current work in this laboratory.
Whilstsubconﬂuentcellsareacknowledgedtoprovide
optimum mitogenic activity, the mode of action for
allogeneic cells compared to autologous cells is quite
different. Autologous grafts will provide permanent
cover for burns patients, and they were developed as
complete cell sheets for this purpose. One of the
features of keratinocytes is that they display a tightly
regulated proliferation/differentiation behaviour. One
ofthetriggersfordifferentiationiscell-to-cellcontact.
Integrated cell sheets are therefore differentiated cells
which can provide a barrier function but are not as
potent mitogenically as subconﬂuent cells. The sili-
cone membrane delivery technology described in this
publication and elsewhere was developed by the
University of Shefﬁeld and Altrika as a way of
delivering subconﬂuent cells whilst also providing a
wound cover. The approach was initially developed
for use with autologous cells, but has since been
adapted to deliver allogeneic NFKs. One of the
potential drawbacks with delivering subconﬂuent
allogeneic cells is related to their mode of action. In
contrast to autologous cells, which are capable of
permanent take on a wound, allogeneic cells will be
rejected over time, albeit with minimal inﬂammatory
response and no requirement for immunosuppressant
drugs. Their beneﬁt to burns patients is in providing
accelerated healing by potentmitogenic stimulation of
remnant cells in (burn) wounds or donor sites. In such
Fig. 7 History of all the changes that were introduced in the cultured epithelial allograft production system
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123cases it may be desirable to increase the numbers of
allogeneic cells being delivered to a particular wound
site, in effect increasing the mitogenic dose. If the
numbers of subconﬂuent cells are increased, eventu-
ally they will reach conﬂuency and the deﬁned
differentiation pathway will be activated. There is
therefore a balance between cells displaying optimum
mitogenic activity in a subconﬂuent state, and increas-
ing mitogenic activity by having higher cell numbers,
but in a differentiated state. The clinical outcomes of
the two approaches have, unfortunately, not yet been
evaluatedinacontrolledmanner.Togenerateanintact
sheetofNFKs,andbuildupcellnumbers,stratiﬁcation
of cells is required and previously this has required the
use of a serum-containing media. Allografts produced
in an animal-free stratiﬁcation system, containing
animal product-free soy peptone (BBL
TM Phytone
TM
Peptone, BD Biosciences), are currently being vali-
dated. The relatively high cost and limitations on
therapeutic use of some of the animal product-free
alternatives could delay routine clinical application of
these Phase 6 allografts. Some manufacturers do not
wish to disclose the exact composition of proprietary
mediaoradjuvantsandtheclinicalindemnityissuesof
using these products in patients are such that some of
these promising media are currently not licensed for
such use (Bullock et al. 2006).
In summary, quality controlled batch productions
of consistent allografts have been cryopreserved for
off-the-shelf use. The developments outlined above
have signiﬁcantly increased the performance, usabil-
ity, quality and safety of our allografts. Depending on
the wound type, treatment regime, surgical tech-
niques and clinical timing, speciﬁc NFK allograft
delivery formats can be prepared. As such, we are
now focussing on the development and comparison of
additional allograft delivery formats, such as animal-
free multilayer sheets, monolayer cultures on silicone
substrates, lyophilised keratinocytes and composite
living skin equivalents.
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